Domino’s Pizza Australia rejects Bain Capital takeover report after share surge
Shareholders of Mural Oncology plc (NASDAQ:MURA) approved the proposed acquisition of the company by XRA 5 Corp., a wholly-owned subsidiary of XOMA Royalty Corporation, at meetings held Friday. The acquisition is to be completed through a scheme of arrangement under Irish law, as outlined in a transaction agreement dated August 20, 2025.
At the special Scheme Meeting, shareholders voted to approve the scheme of arrangement, with 10,103,706 votes in favor, 81,149 against, and 52,031 abstentions. Of the nine shareholders of record voting on the proposal, eight voted in favor and one voted against, representing 99.20% and 0.79% of those voting, respectively. The approval met the requirements of a majority in number of shareholders and at least 75% of the value of shares voted.
A second proposal to adjourn the Scheme Meeting was not presented, as sufficient votes were received to approve the scheme.
At the subsequent extraordinary general meeting, shareholders also approved the scheme of arrangement, with 10,607,228 votes in favor, 89,435 against, and 13,056 abstentions. An additional proposal to amend the company’s articles of association, ensuring that any shares issued after the voting record time would be subject to the scheme or acquired by the subsidiary for the scheme consideration, was approved with 10,647,967 votes in favor, 48,436 against, and 13,316 abstentions.
A proposal to adjourn the extraordinary general meeting was not presented, as the required votes were obtained for the main proposals.
Based on the results of the meetings, the acquisition is expected to be completed during the fourth quarter of 2025, subject to customary closing conditions and the sanction of the scheme by the High Court of Ireland.
This article is based on a press release statement filed with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.